5.9 C
New York
Friday, March 29, 2024

Flexion Therapeutics Just Hit A Major Milestone

Courtesy of Benzinga.

Flexion Therapeutics Just Hit A Major Milestone

Flexion Therapeutics Inc (NASDAQ: FLXN) announced last week it has received regulatory approval for its Zilretta therapy represents a “monumental milestone” for the company, BMO Capital Markets analyst Gary Nachman commented in a research report. The analyst maintains an Outperform rating on Flexion’s stock with a price target boosted from $35 to $37 even though the approval was heavily expected.

tipranks.png

Among the multiple highlights for Flexion was diabetic data from a small study that wasn’t expected, Nachman commented. The data showed a modest glucose level change for just the Zilretta arm and didn’t include the IR triamcinolone arm that showed a significantly larger change. This surprise “opens the door to talk about the full diabetic data when Flexion promotes Zilretta (15-20% of OA knee patients have diabetes).”

“Importantly, we see a solid outcome with the label, and particularly some upside with mention of positive diabetic data that can be used as a key marketing hook,” the analyst added.

Finally, another welcome surprise comes from refrigeration as the label stated that its therapy can be stored at room temperature for up to six weeks if a fridge is not available, the analyst added. Refrigeration has been highlighted as a “potential sticking point” but is now “less of a concern.”

At time of publication, shares of Flexion were down 6.16 percent at $28.09.

Related Links:

The Week Ahead: New IPOs, Bank Earnings, And Some Notable FDA Actions

Mid-Morning Market Update: Markets Mostly Flat; Axalta Lowers 2017 Forecast

Latest Ratings for FLXN

Date Firm Action From To
Oct 2017 BMO Capital Maintains Outperform
Aug 2017 Northland Securities Initiates Coverage On Outperform
Dec 2016 Raymond James Initiates Coverage On Strong Buy

View More Analyst Ratings for FLXN


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,449FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x